ISHIDA Ryosuke

Researcher Information

Research Areas

• Life sciences / Pharmaceuticals - chemistry and drug development

Academic & Professional Experience

• 2024/11 - Today  Institute of Science TokyoInstitute of Integrated Science, Laboratory of Biomaterials and Bioengineering非常勤講師
• 2024/11 - Today  Nagoya City UniversityGraduate School of Pharmaceutical SciencesAssistant professor
• 2021/09 - 2024/10  Tokyo Medical and Dental UniversityInstitute of Biomaterials and BioengineeringAssistant professor
• 2021/04 - 2021/08  Stanford UniversitySchool of MedicinePostdoctral Scholar
• 2019/04 - 2021/03  Harvard Medical SchoolResearch Fellow
• 2019/04 - 2021/03  Dana-Farber Cancer InstituteResearch Fellow
• 2018/04 - 2019/03  Ritsumeikan UniversityResearch Organization of Science and TechnologyPostdoctoral Fellow
• 2017/04 - 2018/03  Osaka UniversityGraduate School of Pharmaceutical SciencesSpecially appointed assistant professor

Education

• 2014/04 - 2017/03  Osaka University  Graduate School of Pharmaceutical Sciences  Advanced Pharmaco-science
• 2012/04 - 2014/03  Osaka University  Graduate School of Science  Department of Chemistry
• 2008/04 - 2012/03  Osaka University  School of Science  Department of Chemistry

Published Papers

• Development of selective RyR2 inhibitors with a pharmacophore containing a parabanic acid skeleton

  Ryosuke Ishida; Xi Zeng; Nagomi Kurebayashi; Takashi Murayama; Shuichi Mori; Yuga Yamamoto; Hiroyuki Kagechika

  RSC Medicinal Chemistry Royal Society of Chemistry (RSC) 2025 [Refereed]
  
• Anti-Inflammatory Effects of a Novel Nuclear Factor–κB Inhibitory Derivative Derived from Pyrazolo[3,4-d]Pyrimidine in Three Inflammation Models

  Hiroyuki Baba; Tadashi Hosoya; Ryosuke Ishida; Kenpei Tai; Saki Hatsuzawa; Yuma Kondo; Hiroyuki Kusuhara; Hiroyuki Kagechika; Shinsuke Yasuda

  Journal of Pharmacology and Experimental Therapeutics American Society for Pharmacology & Experimental Therapeutics (ASPET) 388 (3) 788 - 797 0022-3565 2024/01 [Refereed]
  
• Discovery and Structure-Activity Relationship of a Ryanodine Receptor 2 Inhibitor.

  Ryosuke Ishida; Xi Zeng; Nagomi Kurebayashi; Takashi Murayama; Shuichi Mori; Hiroyuki Kagechika

  Chemical & pharmaceutical bulletin 72 (4) 399 - 407 2024 [Refereed]
  
• A potent and selective cis-amide inhibitor of ryanodine receptor 2 as a candidate for cardiac arrhythmia treatment

  Ryosuke Ishida; Nagomi Kurebayashi; Hiroto Iinuma; Xi Zeng; Shuichi Mori; Masami Kodama; Takashi Murayama; Hiroyuki Masuno; Fumi Takeda; Masatoshi Kawahata; Aya Tanatani; Aya Miura; Hajime Nishio; Takashi Sakurai; Hiroyuki Kagechika

  European Journal of Medicinal Chemistry 0223-5234 2023/12 [Refereed]
  
• Screening for Novel Type 2 Ryanodine Receptor Inhibitors by Endoplasmic Reticulum Ca²⁺Monitoring

  Mai Takenaka; Masami Kodama; Takashi Murayama; Mari Ishigami-Yuasa; Shuichi Mori; Ryosuke Ishida; Junji Suzuki; Kazunori Kanemaru; Masami Sugihara; Masamitsu Iino; Aya Miura; Hajime Nishio; Sachio Morimoto; Hiroyuki Kagechika; Takashi Sakurai; Nagomi Kurebayashi

  Molecular Pharmacology American Society for Pharmacology & Experimental Therapeutics (ASPET) 104 (6) 275 - 286 0026-895X 2023/09 [Refereed]
  
• Drug development for the treatment of RyR1-related skeletal muscle diseases.

  Takashi Murayama; Nagomi Kurebayashi; Ryosuke Ishida; Hiroyuki Kagechika

  Current opinion in pharmacology 69 102356 - 102356 2023/04 [Refereed]
  
• Targeting Cellular Retinoic Acid Binding Protein 1 with Retinoic Acid-like Compounds to Mitigate Motor Neuron Degeneration

  Jennifer Nhieu; Liming Milbauer; Thomas Lerdall; Fatimah Najjar; Chin-Wen Wei; Ryosuke Ishida; Yue Ma; Hiroyuki Kagechika; Li-Na Wei

  International Journal of Molecular Sciences MDPI AG 24 (5) 4980 - 4980 2023/03 [Refereed]
  
• A reconstituted depolarization-induced Ca2+ release platform for validation of skeletal muscle disease mutations and drug discovery

  Takashi Murayama; Nagomi Kurebayashi; Takuro Numaga-Tomita; Takuya Kobayashi; Satoru Okazaki; Kyosuke Yamashiro; Tsutomu Nakada; Shuichi Mori; Ryosuke Ishida; Hiroyuki Kagechika; Mitsuhiko Yamada; Takashi Sakurai

  Journal of General Physiology Rockefeller University Press 154 (12) 0022-1295 2022/11 [Refereed]
  
• Development of a water-soluble ryanodine receptor 1 inhibitor

  Ryosuke Ishida; Shuichi Mori; Takashi Murayama; Ayaka Nakamichi; Xikun Chai; Nagomi Kurebayashi; Hiroto Iinuma; Hiroyuki Kagechika

  Bioorganic & Medicinal Chemistry 0968-0896 2022/11 [Refereed]
  
• Mice with R2509C-RYR1 mutation exhibit dysfunctional Ca2+ dynamics in primary skeletal myocytes

  Yoshitaka Tsuboi; Kotaro Oyama; Fuyu Kobirumaki-Shimozawa; Takashi Murayama; Nagomi Kurebayashi; Toshiaki Tachibana; Yoshinobu Manome; Emi Kikuchi; Satoru Noguchi; Takayoshi Inoue; Yukiko U. Inoue; Ichizo Nishino; Shuichi Mori; Ryosuke Ishida; Hiroyuki Kagechika; Madoka Suzuki; Norio Fukuda; Toshiko Yamazawa

  Journal of General Physiology Rockefeller University Press 154 (11) 0022-1295 2022/10 [Refereed]
  
• Synthesis and Structure–Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold

  Zhengnian Li; Ryosuke Ishida; Yan Liu; Jinhua Wang; Yina Li; Yang Gao; Jie Jiang; Jianwei Che; Jason M. Sheltzer; Matthew B. Robers; Tinghu Zhang; Kenneth D. Westover; Behnam Nabet; Nathanael S. Gray

  European Journal of Medicinal Chemistry 0223-5234 2022/08 [Refereed]
  
• Fasciospyrinadinone and Fasciospyrinadinol, Novel 3-Alkylpyridine Sesquiterpenoids from An Indonesian Marine Sponge, as Selective Growth Inhibitors of the Cancer Cells under Nutrient Starvation

  Matsumoto, H; Hisa, T; Toda, K; Ishida, R; Setiawan, A; Arai, M; Kotoku, N

  Heterocycles 103 (2) 827 - 838 2021/03 [Refereed]
  
• Selective cytotoxicity of epidithiodiketopiperazine DC1149B, produced by marine-derived Trichoderma lixii on the cancer cells adapted to glucose starvation

  Rui Tang; Atsushi Kimishima; Ryosuke Ishida; Andi Setiawan; Masayoshi Arai

  Journal of Natural Medicines Springer Science and Business Media LLC 74 (1) 153 - 158 1340-3443 2019/08 [Refereed]
  
• Structure–Activity Relationship of Biakamide, Selective Growth Inhibitors under Nutrient-Starved Condition from Marine Sponge

  Ryosuke Ishida; Hirokazu Matsumoto; Sayaka Ichii; Motomasa Kobayashi; Masayoshi Arai; Naoyuki Kotoku

  Chemical and Pharmaceutical Bulletin 0009-2363 2019/03 [Refereed]
  
• Biakamides A–D, Unique Polyketides from a Marine Sponge, Act as Selective Growth Inhibitors of Tumor Cells Adapted to Nutrient Starvation

  Naoyuki Kotoku; Ryosuke Ishida; Hirokazu Matsumoto; Masayoshi Arai; Kazunari Toda; Andi Setiawan; Osamu Muraoka; Motomasa Kobayashi

  The Journal of Organic Chemistry 0022-3263 2017/02 [Refereed]
  
• Marine spongean polybrominated diphenyl ethers, selective growth inhibitors against the cancer cells adapted to glucose starvation, inhibits mitochondrial complex II

  Masayoshi Arai; Dayoung Shin; Kentaro Kamiya; Ryosuke Ishida; Andi Setiawan; Naoyuki Kotoku; Motomasa Kobayashi

  Journal of Natural Medicines Springer Science and Business Media LLC 71 (1) 44 - 49 1340-3443 2016/07 [Refereed]
  

Other link

researchmap

https://researchmap.jp/Ryosuke_Ishida